Natalie DiMambro, VP product commercialisation and training, Within3, explores the technologies and trends that are causing leaders to redefine current practices and invest more heavily in innovation to stay ahead of the curve in 2023.
Key insights:
- Covid-19, climate change, and the swift evolution of AI have changed the playing field, and life science companies must modernise and digitise in order to keep up.
- Pharma companies must confront clinical trial enrolment. Nearly 85% of trials are delayed due to enrolment issues, combined with low trial retention rates.
- Virtual asynchronous engagement would save patients hours of travel time and inconvenience.
- Increasing diversity is firmly on the agenda for 2023, with 61% of pharmaceutical companies saying they have concrete goals to enhance diversity in clinical trials.
This year, many factors will influence the life science industry, forcing leaders to re-evaluate current practices and invest more heavily in innovation. Covid-19, climate change, and the swift evolution of artificial intelligence (AI) have changed the playing field, and life science companies must modernise and digitise in order to keep up.